Hillchol

Description

Proven efficacy: Robust immunity against cholera, which can significantly reduce cholera burden and severity, has been demonstrated at each step comparable to other OCVs.
Ease of Administration: Oral delivery method made convenient for mass immunization campaigns.
Broad Age Range: Safe for children and adults over the age of 1 year.
Convenient Packaging: A Single dose respule, which can be conveniently packed for multiple doses for ease and precision in storage, transport and administration, has been designed.
Single Strain Formulation: Single-strain use simplifies manufacturing and enables large-scale production while retaining protection.
Engineered Strain: Utilizes a formalin-inactivated V. cholerae O1 El Tor strain with stable expression of Ogawa and Inaba O1 LPS antigens.
Robust Antigen Expression: Maintains effective immunogenicity.
Efficient Manufacturing: Scalable efficient production and broad coverage are possible as the components needed are simplified and minimized.
Innovative Engineering: The novel partial inactivation of the WbeT gene of O1 El Tor Hikojima serotype complements vaccine effectiveness.